Esotid 20 mg Tablet 1 Strip
Item code: 953273

Indications 

Esotid is indicated:
  • To relieve from chronic heartburn symptoms and other symptoms associated with GERD
  • For the healing of erosive esophagitis
  • For maintenance of healing of erosive esophagitis
  • In combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori infection in patients with duodenal ulcer disease.
  • Zollinger-Ellison Syndrome
  • Acid related Dyspepsia
  • Duodenal & Gastric ulcer

Pharmacology 
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. Esomeprazole (S-isomer of omeprazole) is the first single optical isomer of proton pump inhibitor, provides better acid control than racemic proton pump inhibitors.

Absorption: Esomeprazole capsules contain an enteric-coated pellet formulation of esomeprazole magnesium. After oral administration peak plasma levels (Cmax) occur at approximately 1.5 hours (Tmax). The Cmax increases proportionally when the dose is increased, and there is a three-fold increase in the area under the plasma concentration-time curve (AUC) from 20 to 40 mg. At repeated once daily dosing, the systemic bioavailability is approximately 90% compared to 64% after a single dose. The AUC after administration of a single dose of esomeprazole is decreased by 33-53% after food intake compared to fasting conditions. Esomeprazole should be taken at least one hour before meals.

Distribution: Esomeprazole is 97% bound to plasma proteins. Plasma protein binding is constant over the concentration range of 2 20 mmol/L. The apparent volume of distribution at steady state in healthy volunteers is approximately 16 L.

Metabolism: Esomeprazole is extensively metabolized in the liver by the cytochrome P450 (CYP) enzyme system. The metabolites of esomeprazole lack anti-secretory activity. The major part of esomeprazole’s metabolism is dependent upon the CYP2C19 isoenzyme, which forms the hydroxy and desmethyl metabolites. The remaining amount is dependent on CYP3A4 which forms the sulphone metabolite.

Excretion: The plasma elimination half-life of esomeprazole is approximately 1–1.5 hours. Less than 1% of parent drug is excreted in the urine. Approximately 80% of an oral dose of esomeprazole is excreted as inactive metabolites in the urine, and the remainder is found as inactive metabolites in the faeces.

Combination Therapy with Antimicrobials: Esomeprazole magnesium 40 mg once daily is given in combination with clarithromycin 500 mg twice daily and amoxicillin 1000 mg twice daily for 7 days. The mean steady state AUC and Cmax of Esomeprazole increased by 70% and 18%, respectively, during triple combination therapy compared to treatment with Esomeprazole alone. The pharmacokinetic parameters for clarithromycin and amoxicillin are similar during triple combination therapy and administration of each drug alone. However, the mean AUC and Cmax for 14-hydroxyclarithromycin are increased by 19% and 22%, respectively, during triple combination therapy compared to treatment with clarithromycin alone. This increase in exposure to 14-hydroxyclarithromycin is not considered to be clinically significant.

Dosage & Administration

Oral dosage form-
  • Healing of Erosive Esophagitis: 20 mg or 40 mg Once Daily for 4-8 Weeks. The majority of patients are healed within 4 to 8 weeks. For patients who don't heal after 4-8 weeks, an additional 4-8 weeks of treatment may be considered. Maintenance of Healing of Erosive
  • Esophagitis: 20 mg Once Daily (Clinical studies did not extend 6 months).
  • Symptomatic GERD: 20 mg Once Daily for 4 Weeks. If symptoms do not resolve completely after 4 weeks, an additional 4 weeks of treatment may be considered.
  • Helicobacter Pylori eradication: Triple Therapy to reduce the risk of Duodenal Ulcer recurrence-Esomeprazole 40 mg Once Daily for 10 days, Amoxicillin 1000 mg Twice Daily for 10 days, Clarithromycin 500 mg Twice Daily for 10 days.
  • Zollinger-Ellison Syndrome: The dose is 20-80 mg once daily. The dosage should be adjusted individually and treatment continued as long as clinically indicated.
  • Acid-related Dyspepsia: 20-40 mg once daily for 2-4 weeks according to the response.
  • Duodenal ulcer: 20 mg once daily for 2-4 weeks. Gastric ulcer: 20-40 mg once daily for 4-8 weeks.

IV Injection or IV infusion:

GERD with Erosive Esophagitis-
Adult Patients (≥18 years):
  • 20 mg or 40 mg once daily
  • IV Injection: >3 Minutes, IV Infusion: 10-30 minutes
Pediatric Patients (1 year to 17 years)
  • Body weight <55 kg: 10 mg Once daily
  • Body Weight ≥55 kg: 20 once daily
  • 1 month to <1 year: 0.5 mg/kg once daily
  • IV Infusion: 10-30 minutes
Risk reduction of rebleeding of Gastric or Duodenal Ulcers following therapeutic endoscopy in adults-
Adult Patients (≥18 years)
  • 80 mg
  • IV Infusion: 30 minutes, followed by a continuous infusion of 8 mg/h for a total treatment duration of 72 hours.

* চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন

Storage Conditions
Store at a temperature not exceeding 30°C in a dry place. Protect from light and moisture. Keep out of reach of children.

Side Effects
The most frequently occurring adverse events reported with Esotid include headache, diarrhoea, nausea, flatulence, abdominal pain, constipation and dry mouth. There are no difference in types of related adverse events seen during maintenance treatment upto 12 months compared to short term treatment.

Note: Product delivery duration may vary due to product availability in stock.

Disclaimer: The color of the physical product may slightly vary due to the deviation of lighting sources, photography or your device display settings.

Customer Questions and answers :

Login to ask a question